Tenofovir Outperforms Adefovir in Chronic HBV

[Guest guest]

http://www.medpagetoday.com/Gastroenterology/Hepatitis/12012

Tenofovir Outperforms Adefovir in Chronic HBV

By , North American Correspondent, MedPage Today

Published: December 03, 2008

Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine,

Harvard Medical School, Boston. Earn CME/CE credit

for reading medical news

DURHAM, N.C., Dec. 3 -- For patients with chronic hepatitis B infection, the

nucleotide reverse transcriptase inhibitor tenofovir (Viread) was more effective

than adefovir (Hepsera) after 48 weeks of treatment. Action Points

--------------------------------------------------------------------------------

Explain to interested patients that tenofovir (Viread) is well known as an HIV

medication and has been approved for treatment of chronic hepatitis B.

Note that this study reports the 48-week efficacy and safety data on which

approval was based.

The medication, well known in the treatment of HIV, significantly reduced viral

loads and improved histological findings (at P